Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT101 TIL injection versus gemcitabine for recurrent or metastatic cervical cancer
CTR20242671Phase 2Active
- Sponsor
- Clinigen
- Start
- Apr 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous tumor infiltrating lymphocytes GT101 in Cervical Cancer (CC) (2 arms), sponsored by Clinigen. Primary endpoint: Progression-free survival by IRC using RECIST 1.1. Started Apr 2024; status: active.
02
Drugs
autologous tumor infiltrating lymphocytes GT101
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20242671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242671.